Drugs / ERX1000
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04890873 | Oct 2019 → Jul 2023 | obesity disorder | ERX Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07570758 Comparator | May 2026 → May 2027 expected | obesity disorder | ERX Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ERX1000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04890873 ↗ |
| Route | Oral | “single and multiple oral doses of ERX1000” NCT04890873 ↗ |